CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality

Transplant International

Volumn 27, Issue 9, 2014, Pages 956-965

  Rabot, Nolwenn ^a   Büchler, Matthias ^a   Foucher, Yohann ^b   Moreau, Anne ^b   Debiais, Celine ^c   Machet, Marie Christine ^a   Kessler, Michelle ^d   Morelon, Emmanuel ^e   Thierry, Antoine ^c   Legendre, Christophe ^f   Rivalan, Joseph ^g   Kamar, Nassim ^h,i,j   Dantal, Jacques ^b  

^a UNIVERSITÉ DE TOURS   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d CHU NANCY BRABOIS   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h CHU RANGUEIL   (France)

ⁱ CHU PURPAN   (France)

^j UNIVERSITÉ PAUL SABATIER   (France)

more..

Author keywords

calcineurin inhibitor; graft survival; immunosuppression withdrawal; kidney transplant; post transplant lymphoproliferative disorder

Indexed keywords

ANTINEOPLASTIC AGENT; CALCINEURIN INHIBITOR; CREATINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ADJUVANT THERAPY; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG SUBSTITUTION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FRANCE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOCOMPROMISED PATIENT; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREAS TRANSPLANTATION; PATHOLOGY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CALCINEURIN INHIBITORS; CREATINE; DRUG SUBSTITUTION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84906848876     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12375     Document Type: Article

References (39)

1. Caillard S, Porcher R, Provot F, et al,. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol 2013; 31: 1302.
2. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, et al,. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 2010; 25: 2089.
3. Glotz D, Chapman JR, Dharnidharka VR, et al,. The Seville Expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation 2012; 94: 784.
4. Caillard S, Lamy F, Quelen C, et al,. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12: 682.
5. Allen U, Alfieri C, Preiksaitis J, et al,. Epstein-barr virus infection in transplant recipients: summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis 2002; 13: 89.
6. Ho M, Miller G, Atchison RW, et al,. Epstein-Barr virus infection and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876.
7. Hall EC, Pfeiffer RM, Segev DL, et al,. Cumulative incidence of cancer after solid organ transplantation. Cancer 2013; 119: 2300.
8. Leblond V, Davi F, Charlotte F, et al,. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity. J Clin Oncol 1998; 16: 2052.
9. Nelson B, Nalesnik M, Bahler D, el al,. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375.
10. Swinnen L, LeBlanc M, Grogan T, et al,. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008; 86: 215.
11. Tsai D, Hardy C, Tomaszewski J, et al,. Immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076.
12. Reshef R, Vardhanabhuti S, Luskin MR, et al,. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011; 11: 336.
13. Elstrom R, Andreadis C, Aqui N, et al,. Treatment of PTLD with Rituximab or chemotherapy. Am J Transplant 2006; 6: 569.
14. Trofe J, Buell J, Beebe T, et al,. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant tumor Registry experience. Am J Transplant 2005; 5: 775.
15. Opelz G, Dohler B,. Lymphomas after solid organ transplantation: a collaborative transplant Study report. Am J Transplant 2004; 4: 222.
16. Evens A, David K, Helenowski I, et al,. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcome and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038.
17. Swerdlow SH, Webber SA, Chadburn A, Ferry JA,. Posttransplant lymphoproliferative disorders. In:, Swerdlow SH, Campo E, Harris NL, Jaffe ES, eds. WHO Classification of Tumors of Haemotopoietic and Lymphoid Tissue. IARC: Lyon, 2008: 343-350.
18. Quinlan SC, Pfeiffer RM, Morton LM, et al,. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206.
19. Parker A, Bowles K, Bradley J, et al,. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS guidelines. Br J Haematol 2010; 149: 693.
20. Aull M, Buell J, Trofe J, et al,. Experience with 274 cardiac transplant recipients with posttransplantation lymphoproliferative disorder: a report from the Israel Penn International Transplant tumor registry. Transplantation 2004; 78: 1676.
21. Trappe R, Hinrichs C, Appel U, et al,. Treatment of PTLD with Rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009; 9: 2331.
22. Serre JE, Michonneau D, Bachy E, et al,. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int 2014; 1: 182.
23. Saadat A, Einollahi B, Ahmadzad-Asl M, et al,. Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience. Transplant Proc 2007; 39: 1071.
24. Mamzer-Bruneel MF, Lome C, Morelon E, et al,. Durable remissison after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622.
25. Birkeland S, Hamilton-Dutroit S, Bendtzen K,. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Transplantation 2003; 76: 153.
26. Johnson S, Cherikh W, Kauffman H, et al,. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 2006; 6: 2743.
27. Karras A, Thervet E, Le Meur Y, et al,. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant 2004; 4: 1904.
28. Hanto D,. Retransplantation after post-transplant lymphoproliferative diseases (PTLD): when is it safe? Am J Transplant 2004; 4: 1733.
29. Raj R, Frost AE,. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005; 24: 671.
30. Caillard S, Dharnidharka V, Agodoa L, et al,. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
31. Faull R, Hollett P, McDonald S,. Lymphoproliferative disease after renal transplantation in Australia and New Zeland. Transplantation 2005; 80: 193.
32. Euvrard S, Morelon E, Rostaing L, et al,. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329.
33. Campbell S, Walker R, Tai S, et al,. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146.
34. Boratynska M, Smolska D,. Inhibition of mTOR by sirolimus induces remission of post transplant lymphoproliferative disorders. Transpl Int 2008; 21: 605.
35. Pascual J,. Post transplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22: 27.
36. Majewski M, Korecka M, Joergensen J, et al,. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 27: 1710.
37. Majewski M, Korecka M, Kossev P, et al,. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285.
38. Sampaio M, Cho Y, Shah T, et al,. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012; 93: 73.
39. Krams S, Martinez O,. Epstein-Barr virus, rapamycin and host immune responses. Curr Opin Organ Transplant 2008; 13: 563.